AHR and breast cancer: Indeed, the evaluation of an ER+ breast cancer cohort with a 10‐year follow‐up (Fig 6M, Table EV6), identified increased AHR, DDA1, and UBE4B levels in the primary tumors that relapsed (Figs 6O, EV4O and Q, Table EV7).